Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completes
An AstraZeneca-collaborated chronic GVHD trial reports results, a new AZD0780 cholesterol trial finishes, and a contraceptive interaction study stays active, not recruiting.
This week brought posted results on a graft-versus-host disease trial, a completed dyslipidaemia study, and no change to a running pharmacokinetics trial, all tied to AstraZeneca.
- A Phase II trial of acalabrutinib for chronic graft-versus-host disease, which studies how well acalabrutinib works in treating patients with chronic graft versus host disease1, posted results on 2026-10-14. The study is sponsored by Fred Hutchinson Cancer Center with AstraZeneca as a collaborator, and the single treatment arm gave acalabrutinib 100 mg orally twice daily on days 1-281, with enrollment of 51 participants.
- NCT07218900, a Phase II AstraZeneca-sponsored trial called LAZURE testing AZD0780 tablets compared with placebo tablets administered in combination with rosuvastatin tablets on LDL-C in adult Russian participants with dyslipidaemia2, reached completed status, with actual primary and study completion dates of 2026-09-03. The study included approximately 76 randomised participants.2
- NCT07013643, AstraZeneca's Phase I trial on AZD6234 and AZD9550's effect on oral contraceptive pharmacokinetics in overweight or obese women, remains active, not recruiting, with a last update posted on 2026-10-133 and an estimated primary completion date of 2027-07-093.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.